BiotechTube

R-mabHD + ABVD

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hodgkin's Disease

Conditions

Hodgkin's Disease

Trial Timeline

Jul 1, 2011 → Apr 1, 2014

NCT ID
NCT00797472

About R-mabHD + ABVD

R-mabHD + ABVD is a phase 2 stage product being developed by Eli Lilly for Hodgkin's Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT00797472. Target conditions include Hodgkin's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00797472Phase 2UNKNOWN

Competing Products

20 competing products in Hodgkin's Disease

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
77
R-mabHDI and ABVD + ABVDEli LillyPhase 3
77
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
41
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
ABT-199 + KetoconazoleAbbViePhase 1
33
ABT-199 + RifampinAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + Rituximab + BendamustineAbbViePhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85